基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
Aim: To assess the safety and efficacy of basal-supported prandial GLP-1 receptor agonist therapy (BPT)* in type 2 diabetes mellitus (T2DM). Methods: Patients with T2DM, who had previously received insulin injection therapy and who had had their treatment switched to BPT (liraglutide), were retrospectively recruited. The efficacy of BPT was assessed by determining changes in HbA1c, body weight and total daily insulin dose from baseline to 4 months after BPT initiation. Safety was assessed by comparing the frequency of hypoglycemic episodes at baseline and after 4 months. The Wilcoxon test was used to analyze changes in parameters throughout the study period. Results: Twenty-nine patients, previously treated with basal-supported oral therapy (BOT), basal-bolus insulin, or pre-mixed insulin, were recruited. When analyzed together, there was no change in HbA1c throughout the study period, but body weight decreased (baseline 68.8 ± 13.2 kg vs. month 4 67.3 ± 13.1 kg;p < 0.001). Total daily insulin dose decreased after 4 months (baseline 24.4 ± 15.5 U/day vs. month 4 14.7 ± 9.2 U/day;p < 0.001), and there was no change in the frequency of hypoglycemic episodes. Analysis was conducted within sub-groups based on previous treatment modality. In the BOT group, HbA1c decreased from baseline after 2 months and body weight did not change throughout the study period. In both the basal-bolus insulin group and the pre-mixed insulin group, HbA1c remained steady throughout and there was a decrease in body weight. No change in the frequency of hypoglycemia was observed in any of the sub-groups. Conclusion: BPT in T2DM was associated with weight loss without changes in glycemic control over 4 months, suggesting that it may be an effective and safe therapy.
推荐文章
基于肠道菌群调节的GLP-1降糖作用机制研究
肠道菌群
GLP-1
降糖
作用机制
新型小分子GLP-1受体别构调节剂的合成及其活性
GLP-1受体
别构调节剂
吲哚并吡啶酮
合成
构效关系
GLP-1类似物的设计及口服制剂研究
GLP-1类似物
石胆酸
口服制剂
GLP-1对3T3-L1前脂肪细胞增殖及脂联素的影响
肥胖
3T3-L1前脂肪细胞
胰高血糖素样肽-1
细胞增殖
脂联素
实验研究
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Efficacy and Safety of Basal-Supported Prandial GLP-1 Receptor Agonist Therapy
来源期刊 糖尿病(英文) 学科 医学
关键词 BASAL Insulin Combination THERAPY GLP-1 Receptor AGONISTS HBA1C Type 2 Diabetes MELLITUS
年,卷(期) 2017,(3) 所属期刊栏目
研究方向 页码范围 86-95
页数 10页 分类号 R5
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2017(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
BASAL
Insulin
Combination
THERAPY
GLP-1
Receptor
AGONISTS
HBA1C
Type
2
Diabetes
MELLITUS
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
糖尿病(英文)
季刊
2160-5831
武汉市江夏区汤逊湖北路38号光谷总部空间
出版文献量(篇)
293
总下载数(次)
0
总被引数(次)
0
论文1v1指导